Pharmaceuticals, Biotechnology and Life Sciences
Field reps can compliantly create sample orders and fulfill requests from healthcare professionals during remote meetings Rapid pace of Veeva…
BOSTON–(BUSINESS WIRE)–#ADHD—Akili today announced that ENDEAVORTM (AKL-T01) is now available for use by children with attention deficit hyperactivity disorder (ADHD)…
Actinium expects to raise $27.5 million to invest in its Sierra phase 3 trial, as well as other programs with…
PrecisionLife is extending its relationships with some of the largest COVID-19 collaborative research projects as it offers free use of its analytics platform and support from its data and biomedical science teams in the fight against COVID19 coronavirus.
Hemogenyx Pharmaceuticals got European Patent Office’s patent entitled Post-Natal Hemogenic Endothelial Cells and their isolation and use.
Applied DNA Sciences has signed an Agreement with Stony Brook University Hospital (the “Hospital”) to validate and implement the Company’s patent-pending nucleic acid diagnostic (LineaCOVID-19™) to detect and quantify in diagnostic samples the presence of SARS-CoV-2, the virus that causes the disease, COVID-19.
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division of Novartis.
Roche said Monday that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and the European Medicines Agency (EMA) has validated the application for a two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly for relapsing or primary progressive multiple sclerosis (MS).
Sanofi and GSK today announced teaming up to work on a vaccine for COVID-19, as Sanofi will contribute its S-protein COVID-19 antigen, and GSK contributing pandemic adjuvant technology.
BIOGGIO, Switzerland–(BUSINESS WIRE)–The KD Pharma Group (“KD Pharma”) and its partner, SLA Pharma (“SLA”), announced that its new drug candidate…